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Background. There are insufficient data from nationwide surveys on the prevalence of specific psychotic disorders
and associated co-morbidities.
Method. The 2010 Australian national psychosis survey used a two-phase design to draw a representative
sample of adults aged 18–64 years with psychotic disorders in contact with public treatment services from an
estimated resident population of 1464923 adults. This paper is based on data from 1642 participants with an
International Classification of Diseases (ICD)-10 psychotic disorder. Its aim is to present estimates of treated
prevalence and lifetime morbid risk of psychosis, and to describe the cognitive, physical health and substance use
profiles of participants.
Results. The 1-month treated prevalence of psychotic disorders was 3.10 cases per 1000 population aged 18–64 years,
not accounting for people solely accessing primary care services; lifetime morbid risk was 3.45 per 1000. Mean
premorbid intelligence quotient was approximately 0.5 s.D.s below the population mean; current cognitive ability (mea-
sured with a digit symbol coding task) was 1.6 s.D.s below the population mean. For both cognitive tests, higher scores
were significantly associated with better independent functioning. The prevalence of the metabolic syndrome was high,
affecting 60.8% of participants, and pervasive across diagnostic groups. Of the participants, two-thirds (65.9%) were cur-
rent smokers, 47.4% were obese and 32.4% were sedentary. Of the participants, half (49.8%) had a lifetime history of al-
cohol abuse/dependence and 50.8% lifetime cannabis abuse/dependence.
Conclusions. Our findings highlight the need for comprehensive, integrative models of recovery to maximize the
potential for good health and quality of life for people with psychotic illness.
Received 21 August 2013; Revised 5 November 2013; Accepted 9 November 2013; First published online 2 January 2014
Key words: Bipolar disorder, schizo-affective disorder, schizophrenia, speed of information processing, substance abuse.
* Address for correspondence: V. A. Morgan, Ph.D., Neuropsychiatric Epidemiology Research Unit M571, School of Psychiatry and Clinical
Neurosciences, The University of Western Australia, 35 Stirling Highway, Crawley 6009, WA, Australia.
(Email: vera.morgan@uwa.edu.au)
Psychological Medicine (2014), 44, 2163–2176. © Cambridge University Press 2014
doi:10.1017/S0033291713002973
ORIGINAL ARTICLE
The online version of this article is published within an Open Access environment subject to the conditions of the Creative
Commons Attribution licence http://creativecommons.org/licenses/by/3.0/
Introduction
Psychotic illnesses comprise a heterogeneous group
of disorders including schizophrenia, schizo-affective
disorder, bipolar disorder with psychotic features,
depression with psychosis and delusional disorders.
Clinical onset of psychotic disorders occurs most
often in late adolescence/early adulthood. These disor-
ders are generally associated with persistent, or recur-
rent, and often disabling symptoms, and contribute
substantially to the overall burden of years lived
with disability (Vos et al. 2012). Recovery (symptom
remission/reduction and functional improvement;
Leucht & Lasser, 2006) is possible. However, improv-
ing outcome and quality of life for people with psy-
chosis requires more than amelioration of symptoms.
Cognition is impaired in a significant proportion of
people with schizophrenia and is a critical determinant
of poor functional outcome (Green et al. 2000; Gold,
2004). Cognitive impairment may precede illness
onset (Reichenberg et al. 2005; Khandaker et al. 2011),
and intelligence quotient (IQ) tends to decline over
the course of illness (Woodberry et al. 2008). It is also
well established that physical morbidity, especially
cardiometabolic disease, and premature mortality are
elevated in this group (Lawrence et al. 2001; Saha
et al. 2007). In schizophrenia, life expectancy is reduced
by 18.7 years for men and 16.3 years for women, com-
pared with the general population (Laursen, 2011), and
the gap is widening (Saha et al. 2007; Lawrence et al.
2013; Nielsen et al. 2013). Diseases of the circulatory
system influence life expectancy more than death
from external causes (Laursen, 2011). Antipsychotic
medication is likely to contribute to high rates of
cardiometabolic disorders, both directly, as well as
mediated through weight gain side effects (De Hert
et al. 2011). However, metabolic disturbance was
observed in severe mental illness well before the
introduction of antipsychotic medication (Maudsley,
1879), pointing to other key causal factors including
modifiable life-style risks (obesity, smoking, substance
abuse, low levels of physical activity and poor
nutrition). General population studies also report an
association between metabolic disturbance and cog-
nitive dysfunction (Brands et al. 2005; Gao et al.
2008), predominantly in older samples with diabetes.
However, few studies have examined this relationship
in people with psychosis. Some (Dickinson et al. 2008;
Lindenmayer et al. 2012; Han et al. 2013), but not all
(Meyer et al. 2005), studies support the association,
but the direction of causality in a disorder where cog-
nition may be impaired early in its course remains
indeterminate. From a positive perspective, there is
good evidence of the effectiveness of cognitive reme-
diation and other non-pharmacological interventions
in improving specific outcomes in psychotic disorders,
including cognitive function (Wykes et al. 2011) and
physical health (Verhaeghe et al. 2011; Daumit et al.
2013).
The prevalence of common mental disorders is well
documented (Kessler et al. 2007). However, few studies
(Perälä et al. 2007; Kodesh et al. 2012) have reported
estimates for psychotic disorders other than schizo-
phrenia (Saha et al. 2005), and most do not include
co-morbidities. In addition to prevalence estimates
of specific psychotic disorders and co-morbidities, we
also need simultaneously collected descriptive data
on disability and social circumstances. These data are
critical to mapping the extent of burden experienced
across psychotic disorders, as well as identifying
correlates of good outcome, in order to inform policy
development and service planning.
With these data deficits in mind, the aims of the
second Australian national survey of psychosis in
2010 (Survey of High Impact Psychosis; SHIP) were
to estimate treated prevalence of psychosis for people
aged 18–64 years in contact with public mental health
services, including services provided through publicly
funded non-government organizations (NGOs), and to
describe, for these individuals, their mental and physi-
cal health, cognitive and other functioning, substance
use, and personal, social and living circumstances.
This paper reports, for psychosis overall, and for its
component disorders, estimated 1-month treated
prevalence and lifetime morbid risk (LMR), and rates
of co-existing phenomena, focusing on cognition,
physical ill-health and substance abuse. In addition,
we take advantage of this large, unbiased sample
of individuals in contact with treatment services to
(i) examine whether those with greater cognitive im-
pairment have poorer functioning and are at increased
risk of the metabolic syndrome, and (ii) calculate the
independent contribution of modifiable life-style risk
factors to cardiometabolic disease.
Method
Population coverage
The 2010 Australian psychosis survey took place
at seven catchment sites in five Australian states,
covering an estimated resident population aged
18–64 years of 1464923 people, approximately 10%
of Australians in that age range. The study sample
comprised people aged 18–64 years, resident in the
catchment sites and in contact with designated public
mental health services (in-patient, out-patient, ambu-
latory and community mental health) and NGOs sup-
porting people with mental illness. Detailed catchment
profiles are available (Morgan et al. 2011). The census
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of people with psychosis was in March 2010. Inter-
views were conducted between April and Dec-
ember 2010.
Design
A two-phase design was employed (Pickles et al.
1995). In phase 1, a psychosis screener (Jablensky
et al. 1999, 2000) was used to identify individuals likely
to meet diagnostic criteria. In addition to census-
month enumeration, administrative records were
examined in order to identify individuals with psy-
chosis who were in contact with public mental health
services in the 11 months prior to census but not
in the census month. There were 7955 people who
screened positive for psychosis who met eligibility cri-
teria. In phase 2, 1825 people who were screen-positive
in phase 1, and 164 who were screen-negative, were
randomly selected, stratified by site and age group
(18–34 years; 35–64 years) and interviewed. Data
from the screen-negative group enabled estimation of
prevalence without assuming that the psychosis screen
had perfect sensitivity. The design and methodology
have been described in full elsewhere (Morgan et al.
2011, 2012).
A 1-month treated prevalence was estimated per
1000 population aged 18–64 years by age strata and
sex using sampling weights derived from phase 1 to
phase 2 (Alonzo et al. 2003) and by expressing esti-
mated numbers of persons in the screened population
meeting diagnostic criteria as a proportion of the corre-
sponding at-risk resident population of the catchment
areas. LMR was estimated per 1000 population aged
18–45 years by sex using Weinberg’s abridged method
(Jablensky et al. 2011) (see online Supplementary
Methods).
In the present study, descriptive data are for 1642
participants who were screen-positive for psychosis
in phase 1 and who met full International Classifica-
tion of Diseases (ICD)-10 criteria for a psychotic dis-
order in phase 2. Weighted estimates (see online
Supplementary Methods) have been used.
Key assessments
Diagnostic classification. This was made using the
Diagnostic Interview for Psychosis (DIP) (Castle et al.
2006). The DIP contains interview questions and
probes, including items from the World Health
Organization Schedules for Clinical Assessment in
Neuropsychiatry (Wing et al. 1990) mapped onto
the 90 diagnostic items of the Operational Criteria
Checklist for Psychotic and Affective Illness
(OPCRIT) (McGuffin et al. 1991). A computer algor-
ithm provides diagnostic classification in accordance
with ICD-10 and Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) criteria on
the basis of the DIP ratings, thus reducing subjective
bias in the interpretation of symptoms and signs.
Inter-rater reliability was good (see online Sup-
plementary Methods).
Physical health assessment. Physical health assessment
including blood pressure, height, weight and waist
circumference, was undertaken by trained staff follow-
ing standardized procedures and using identical
equipment (see online Supplementary Methods). Parti-
cipants provided fasting venous blood samples for
assays of plasma glucose, triglycerides, high-density
lipoprotein cholesterol and total cholesterol concentra-
tions; standard methods in accredited pathology
laboratories were employed. The World Health Organ-
ization body mass index reference range (World
Health Organization, 2000) was used to classify obes-
ity. Physical activity in the past 7 days was rated
using the International Physical Activity Questionnaire
(Craig et al. 2003) and classified according to Austra-
lian Bureau of Statistics categories (Australian Bureau
of Statistics, 2008). Harmonized criteria (Alberti et al.
2009) were used to determine the metabolic syndrome.
Cognitive assessment. This involved two brief tests:
the National Adult Reading Test-Revised (NART-R;
Nelson & Willison, 1991) and the Digit Symbol
Coding Test (DSCT) from the Repeatable Battery
for the Assessment of Neuropsychological Status
(Randolph, 1998). These tests provide reliable indices
of cognitive ability prior to illness onset (NART-R)
and currently (DSCT), and have been used extensively
in previous studies of schizophrenia (Randolph, 1998;
Smith et al. 1998; Crawford et al. 2001; Wilk et al.
2002; Dickinson et al. 2007). The NART-R Full-Scale
IQ score was used to estimate premorbid IQ. The
stability of NART-estimated intelligence over the long-
term course of schizophrenia has been demonstrated
(Morrison et al. 2000). The DSCT assesses cognitive
processing efficiency. It requires the coordination
and speeded performance of a range of simpler skills
including: visual scanning, relational memory and
motor ability. Lower coding scores signify relatively
poorer performance, that is, greater information pro-
cessing inefficiency. The DSCT is a robust indicator
both of the presence and risk of illness (Dickinson
et al. 2007) and functional outcome in schizophrenia
(Gold et al. 2002).
Course of illness. Course of illness (single episode;
multiple episodes of acute illness with partial/good
recovery; continuous, chronic with/without deterio-
ration) was assessed and rated by the interviewers
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who based their ratings on participant responses
throughout the course of the interview.
Independent functioning. In the 4 weeks prior to
interview, independent functioning was assessed by
interviewers using the Multidimensional Scale of
Independent Functioning (MSIF; Jaeger et al. 2003).
Here we report on the Overall Global Independent
Functioning scale which assessed functioning across
occupational, educational and residential domains,
correcting role functioning for degree of role responsi-
bility, level of support provided, and actual perform-
ance: a score of 1 indicates functioning equivalent
to community norms and 7 indicates total disability.
The MSIF has been validated on samples of people
with schizophrenia (Jaeger et al. 2003) and bipolar dis-
order (Berns et al. 2007) and has been used to assess the
relationship between cognitive function and real-world
outcomes in schizophrenia (Heinrichs et al. 2010). Since
the MSIF does not measure sociability (‘social drive’),
this was rated independently for the past year by the
interviewers on the basis of multiple items in the inter-
view tapping into this domain.
Data analysis
Weighted analysis was done in IBM SPSS Modules
for Complex Samples 21 (IBM, USA), which takes
into account survey design and sampling weights.
For the most part, population estimates are presented
as percentages or means, with 95% confidence inter-
vals (CIs). Conservatively, comparisons were con-
sidered statistically significant when CIs did not
overlap (Julious, 2004). The SPSS Complex Samples
General Linear Model was used to examine the associ-
ation between cognition and cardiometabolic profile/
risk factors. Complex Samples Logistic Regression
was used to model univariate and multivariate rela-
tionships between the metabolic syndrome and life-
style risk factors. S.D.s of means were calculated using
Stata/IC 12.0 survey commands (StataCorp LP, USA).
Results
The 1-month treated prevalence of psychotic
disorders and lifetime estimate of morbid risk
The 1-month treated prevalence of psychotic disorders
in public mental health services was 3.10 cases per
1000 population aged 18–64 years (Table 1).
Schizophrenia/schizo-affective disorder was the most
prevalent diagnosis, and twice as prevalent in males
as females. Bipolar disorder with psychosis was the
next most frequent diagnosis, occurring substantially
less frequently than schizophrenia/schizo-affective dis-
order and at comparable rates in males and females.Ta
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The prevalence of depressive psychosis and delusional
disorders was relatively low. LMR rates (Table 1) were
somewhat higher than prevalence estimates but with
comparable patterns of occurrence and sex differences.
The 12-month interviewed sample
The number of people meeting ICD-10 criteria for
a psychotic disorder was 1642 (weighted n=7112).
Online Supplementary Tables S1–S14 include descrip-
tive data on the interviewed sample by diagnostic
group. The proportion of males was 61.1% (range
39.7–70.4% across the five diagnostic groups). The
mean age at onset was 24 years (range 23–25 years)
and the mean age at interview was 39 years (range
39–42 years). Mean duration of illness was 16 years
(range 15–17 years) (see online Supplementary Tables
S1 and S3).
Course of illness and functioning
The majority of participants (61.6% in total, range
54.8–77.6% across the diagnostic groups) were rated
as having multiple episodes of illness with good or
partial recovery between episodes (online Supplemen-
tary Table S3). For one-third (32.5%), however, course
of illness was continuous. The proportion was highest
for schizophrenia (38.8%) and lowest for bipolar
disorder with psychosis (18.9%); this difference was
significant (p<0.000). The mean score for global inde-
pendent functioning was 3.5. The highest mean score
(indicating poorest performance) was for schizo-
phrenia and the lowest was for depressive psychosis
(online Supplementary Table S9). Overall, one-quarter
(23.5%) of participants were rated as normal or very
mildly disabled relative to community norms with
respect to independent functioning while almost
another quarter (22.2%) were assessed as significantly,
extremely or totally disabled. In addition, almost
two-thirds (65.1%) of participants were rated as having
obvious or severe dysfunction in social drive. This
figure was highest for depressive psychosis (79.4%)
and lowest for bipolar disorder with psychosis
(58.1%), a significant difference.
Cognitive impairment
The proportions of participants with valid NART-R
and DSCT data were 84.7% and 88.7%, respectively.
Mean estimated premorbid IQ (NART-R), 98.0
(S.D.=11.3), was approximately 0.5 s.D.s below the
population mean (Nelson & Willison, 1991) of 107.4
(S.D.=17.1) (online Supplementary Table S5). Current
cognitive ability (DSCT) was markedly impaired: par-
ticipants had a mean score of 38.3 (S.D.=10.6), which
is 1.6 s.D.s below the population mean (Australian
Schizophrenia Research Bank, 2011) of 54.2 (S.D.=9.8).
DSCT raw scores were also examined as a function
of age group (Table 2). In both the survey and
Australian normative samples, younger age groups
performed better than older age groups. However,
mean scores for the youngest survey participants
were significantly lower than those for all normative
age groups, including the oldest. Each diagnostic
group scored below the population mean on the
NART-R, albeit within 1 s.D., ranging from 0.4 s.D.s (bi-
polar disorder with psychosis) to 0.7 s.D.s (delusional
disorders) below the norm (online Supplementary
Table S5). Participants with schizophrenia scored sign-
ificantly lower than those with bipolar disorder. For
the DSCT, each diagnostic group scored over 1 s.D.
below the norm, ranging from 1.2 s.D.s (depressive
psychosis) to 1.7 s.D.s (schizophrenia, schizo-affective
disorder and delusional disorders) below the norm
(online Supplementary Table S5). Participants with
schizophrenia scored significantly lower than those
with bipolar disorder or depressive psychosis.
Finally, higher NART-R and DSCT scores were both
significantly associated with lower (better) scores on
global independent functioning [general linear model
regression estimates of −1.2 (95% CI −1.7 to −0.7)
and −2.7 (95% CI −3.2 to −2.3), respectively].
Cardiometabolic disease and its risk factors
Of participants who provided fasting blood samples
(n=1155, 70.3% of the total), 60.8% met harmonized
criteria (Alberti et al. 2009) for the metabolic syndrome.
The proportions meeting thresholds for each compo-
nent of the metabolic syndrome, or in treatment for
the component condition, were: increased abdominal
adiposity, 84.2%; reduced high-density lipoproteins,
58.1%; elevated triglycerides, 55.5%; elevated blood
pressure, 54.4%; and elevated glucose, 35.3% (online
Supplementary Table S4). The prevalence of the
Table 2. Current cognitive functiona by age group
Age group,
years
2010 Australian
psychosis survey
Australian
population normsb
Mean (S.D., 95% CI) Mean (S.D.)
18–24 41.7 (11.0, 39.1–44.2) 59.9 (9.6)
25–34 40.2 (9.9, 39.1–41.3) 59.7 (9.1)
35–44 38.7 (9.8, 37.6–39.9) 55.5 (8.3)
45–54 34.7 (10.4, 33.0–36.4) 51.8 (8.4)
55–64 33.6 (11.2, 31.6–35.6) 48.1 (8.9)
S.D., Standard deviation; CI, confidence interval.
a Based on speed of information processing using the
Digit Symbol Coding Test (Randolph, 1998).
b Australian Schizophrenia Research Bank (2011).
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metabolic syndrome and its component criteria was
comparable across the diagnostic groups.
Many participants had potentially modifiable life-
style risk factors for cardiometabolic disease (online
Supplementary Table S4). Two-thirds (65.9%) were
current smokers (males 70.3%; females 59.0%), con-
suming 21 cigarettes per day on average, with 40.1%
of the total meeting criteria for high or very high nic-
otine dependence (Fagerström Test for Nicotine
Dependence; Heatherton et al. 1991). Of the partici-
pants, one-third (32.4%) was assessed as being seden-
tary in the last 7 days, with a further 63.6% recording
low levels of activity. As many as 70.6% had one
or fewer serves of fruit per day, while 48.1% had one
or fewer serves of vegetables per day. In addition to
84.2% meeting the abdominal adiposity threshold for
the metabolic syndrome, 47.4% had a body mass
index in the obese range. Almost two-fifths (38.8%)
of participants reported weight gain associated with
medication use: the mean reported gain over the pre-
vious 6 months was 9.5 kg.
Table 3 shows the relationship between cognition
and the metabolic syndrome. Lower current cognitive
performance (DSCT) was significantly associated
with having the metabolic syndrome and with meeting
threshold levels for each of its criteria. By contrast,
there were no significant associations between premor-
bid IQ (NART-R) and the same measures. Examining
life-style risk factors, lower current cognitive perform-
ance was significantly associated with body mass
index, smoking and physical activity level, but not
with fruit and vegetable consumption. Lower premor-
bid IQ was significantly associated with smoking only.
Further analysis was undertaken to assess the
independent contribution of modifiable life-style risk
factors to the metabolic syndrome. In univariate ana-
lyses, current smoking, body mass index and activity
level, but not vegetable or fruit consumption, were
significant predictors. In the unadjusted multivariate
model, current smoking and body mass index
remained significant. These variables were retained
and the model was adjusted for sex, age, illness dur-
ation and socio-economic status. Further adjustment
was made for potential confounders, first separately
for medication use, diagnostic classification and cur-
rent cognitive ability, and then for the three potential
confounders combined. The results were virtually un-
changed in all models and none of the added variables
was significant (see Table 4).
Co-morbid substance abuse
Almost half (49.8%) of the participants had a lifetime
history of alcohol abuse/dependence (males 57.2%;
females 38.0%). The proportion was highest for
delusional disorder (54.1%) and lowest for
schizo-affective disorder (46.5%). Based on consump-
tion over the past year, 17.0% of the total sample met
criteria for hazardous drinking and 12.9% for harmful
or dependent drinking (Alcohol Use Disorder
Identification Test) (Babor et al. 2001). The proportion
with current harmful or dependent drinking was high-
est for depressive psychosis (21.9%) and lowest for
schizophrenia (11.3%). In addition, 50.8% had a life-
time history of cannabis abuse/dependence (males
60.2%; females 36.2%). The proportion was highest
for schizophrenia (54.1%) and lowest for depressive
psychosis (40.5%). Over the past year, 30.8% of all par-
ticipants had been using cannabis; 11.9% were using it
daily. People with schizophrenia were least likely to be
using cannabis daily (10.0%) and those with schizo-
affective disorder were most likely (15.6%) (see online
Supplementary Tables S7 and S8).
Discussion
The 1-month treated prevalence estimate for psy-
chosis in Australia is 3.10 per 1000 population
aged 18–64 years, while the LMR is estimated to be
3.45 per 1000 population aged 18–45 years. These
figures do not take into account people solely accessing
primary care or private mental health services for their
disorder, or not in contact with any treatment service.
Mindful of the more restricted age range of the LMR,
the Australian LMR estimate is relatively low com-
pared with international estimates (median per 1000
=7.20, interquartile range=4.7–17.20) (Saha et al.
2005). Estimates from a nationally representative sam-
ple in Finland have reported a lifetime prevalence for
psychotic disorders, a value usually lower than LMR,
as high as 34.8 per 1000 (Perälä et al. 2007). In keeping
with the relatively low prevalence of psychotic dis-
orders, the estimates for the subtypes are also low
compared with published estimates. In particular, the
estimated LMR for bipolar disorder with psychosis
was only 0.76 per 1000. Since our survey was specifi-
cally designed to capture psychotic disorders rather
than all mood disorders, the estimates apply to affect-
ive psychoses only, and represent a lower boundary.
In keeping with previous findings (Reichenberg et al.
2005; Khandaker et al. 2011), we found cognitive im-
pairment in people with psychosis that preceded ill-
ness onset. The mean estimated premorbid IQ for
the survey participants was approximately 0.5 s.D.s
below the population mean, similar to results by
Morrison et al. (2000) of 96.9 (S.D. =14, range 69–124),
and to S.D.s of 0.4 and 0.5 below the population mean
reported in two recent reviews (Woodberry et al.
2008; Khandaker et al. 2011). Our data also support
the evidence of further cognitive impairment after
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illness onset (with DSCT scores slightly more than 1.5
s.D.s below the population mean) and of associated
functional deficits, with both current and premorbid
cognitive impairment related to poorer independent
functioning. Finally, we found that current cognitive
impairment, as measured by a speed of information
processing task, was associated with cardiometabolic
measures and life-style risk factors for cardiometabolic
disease although we were unable to explore direction-
ality in our cross-sectional data. The specific associ-
ation with speed of information processing has been
observed in general population studies (Brands et al.
2005), as well as schizophrenia studies (Dickinson
et al. 2008; Lindenmayer et al. 2012). The pathophysi-
ology underlying the association between metabolic
dysregulation and cognition remains unclear. It is
Table 3. Cognitive function and metabolic parameters
Premorbid IQa Current cognitive functionb
Mean F, p Mean F, p
Metabolic syndromec and threshold criteria
Met criteria for the metabolic syndromec
No 98.5 F=0.1, p=0.717 40.2 F=21.3, p=0.000
Yes 98.2 36.9
Abdominal obesity
No 97.3 F=1.1, p=0.289 39.8 F=4.3, p=0.039
Yes 98.2 38.0
Reduced high-density lipoprotein levels
No 99.3 F=3.8, p=0.052 39.5 F=9.5, p=0.002
Yes 97.8 37.3
Elevated triglyceride levels
No 98.3 F=0.0, p=0.903 39.6 F=13.9, p=0.000
Yes 98.4 37.0
Elevated glucose levels
No 98.2 F=0.1, p=0.703 39.2 F=12.6, p=0.000
Yes 98.5 36.7
Elevated blood pressure
No 98.3 F=0.2, p=0.694 39.7 F=20.6, p=0.000
Yes 98.0 37.0
Life-style risk factors
Current smoker
No 100.1 F=20.2, p=0.000 39.3 F=6.5, p=0.011
Yes 96.9 37.6
Body mass index
Underweight/normal 97.7 F=0.4, p=0.690 40.0 F=4.4, p=0.012
Overweight 98.5 38.2
Obese 97.9 37.6
Level of physical activity
Very low 98.1 F=0.2, p=0.903 36.8 F=3.1, p=0.025
Low 98.0 38.8
Moderate 97.6 39.0
High 102.2 39.3
One or fewer serves of vegetables per day
No 97.6 F=1.2, p=0.267 38.2 F=0.1, p=0.802
Yes 98.4 38.3
One or fewer serves of fruit per day
No 97.8 F=1.6, p=0.212 38.3 F=0.2, p=0.688
Yes 98.7 38.1
IQ, Intelligence quotient.
a Measured using the National Adult Reading Test-Revised (Nelson & Willison, 1991).
b Based on speed of information processing using the Digit Symbol Coding Test (Randolph, 1998).
c Based on harmonized criteria (Alberti et al. 2009).
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likely to involve the joint effects of hyperglycaemia
and hyperinsulinaemia increasing the risk of cerebral
vascular abnormalities and structural brain changes
either directly or mediated by mechanisms such as
altered synaptic plasticity, oxidative stress, advanced
glycation end-products and inflammation (Biessels
et al. 2006; Panza et al. 2010; Jones, 2012). While an
association has been reported between metabolic dis-
turbance and cognitive deficits, including speed of pro-
cessing deficits, in schizophrenia (Meyer et al. 2005;
Lindenmayer et al. 2012), further investigation of
possible bidirectionality is warranted in psychotic ill-
ness where cognitive impairment antedates the onset
of metabolic disorders. In addition, cognitive impair-
ment may exacerbate vulnerability for the metabolic
syndrome via a variety of mechanisms including
reduced responsiveness to public health measures
targeting life-style risk factors.
Some 60.8% of participants met criteria for the
metabolic syndrome, significantly higher than the
prevalence of 32.5% for schizophrenia reported in a
recent systematic review (Mitchell et al. 2013). Our
prevalence is similar to the 54% reported for a clinical
sample using more conservative International Diabetes
Federation criteria (International Diabetes Federation,
2006) in one of a very few Australian studies (John
et al. 2009), although another study found a 68%
rate in a chronic, predominantly hospitalised, sample
(Tirupati & Chua, 2007). Our data underline the critical
role of modifiable life-style risk factors for cardiometa-
bolic disease, especially body mass index and smoking.
It has been proposed that smoking cessation would
produce a 75% reduction in high/very high risk of
cardiovascular disease in people with schizophrenia
(Bobes et al. 2010). Of concern, based on comparable
subsamples from the 2010 and 1997–1998 national
psychosis surveys, smoking rates had not changed
over 13 years (Morgan et al. 2012). Cardiorespiratory
fitness has also been associated with reduced all-cause
mortality as well as mortality from cardiovascular dis-
ease (Wildgust & Beary, 2010) and there is growing
evidence for the mental health benefits of physical ex-
ercise (Erickson et al. 2011). However, 32.4% of partici-
pants were sedentary and a further 63.6% recorded
low levels of activity. Proportions for the Australian
population in the same age range are 18.0% and
54.0%, respectively (Morgan et al. 2011, 2012). We did
not find that diet was related to the metabolic syn-
drome. A recent review of this area confirms that peo-
ple with schizophrenia have a poor diet, but notes that
evidence linking diet to metabolic abnormalities in this
population is equivocal and further research is needed
Table 4. Life-style risk factors and the metabolic syndrome
Univariate
unadjusted odds
ratio (95% CI)
Multivariate
unadjusted odds
ratio (95% CI)
Multivariate
adjusteda odds
ratio (95% CI)
Multivariate
adjustedb odds
ratio (95% CI)
Life-style risk factors
Currently a smoker
Yes 1.3 (1.0–1.7)* 1.9 (1.4–2.6)* 2.2 (1.6–3.0)* 2.3 (1.6–3.2)*
No Reference Reference Reference Reference
Body mass index
Underweight or normal Reference Reference Reference Reference
Overweight 4.8 (3.2–7.2)* 5.3 (3.5–8.0)* 5.3 (3.5–8.2)* 4.9 (3.1–7.8)*
Obese 13.9 (9.4–20.7)* 16.6 (11.0–25.2)* 17.9 (11.6–27.7)* 16.8 (10.4–27.0)*
Activity level
Very low (sedentary) 2.5 (1.3–5.1)* – – –
Low 1.8 (0.9–3.5) – – –
Moderate or high Reference – – –
One or fewer serves of vegetables per day
Yes 1.1 (0.9–1.4) – – –
No Reference – – –
One or fewer serves of fruit per day
Yes 0.9 (0.7–1.2) – – –
No Reference – – –
CI, Confidence interval.
a Adjusted for sex, age, illness duration and socio-economic status.
b Adjusted for sex, age, illness duration and socio-economic status, and diagnosis, cognition and medication.
* p<0.05.
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(Dipasquale et al. 2013). Intervention trials support the
effectiveness of life-style modifications in this popu-
lation (Verhaeghe et al. 2011; Daumit et al. 2013).
Nonetheless, we need to know more about how best
to promote, implement and support life-style changes
in the community context, especially when the ma-
jority of our participants experience impaired social
drive.
People with severe mental illness also face inequal-
ities in physical health service delivery (Lawrence &
Kisely, 2010). We have previously reported that the
proportion of survey participants having a blood test
in the previous year had dropped markedly since the
1997–1998 survey, from 83.1% to 64.8%, while the pro-
portion having had a physical examination had also
dropped – from 79.6% to 66.1% (Morgan et al. 2012).
Moreover, only half (51.7%) of 2010 survey partici-
pants with hypertension were on medication for their
condition; the figures for diabetes/hyperglycaemia
and hypercholesterolaemia were even lower, at 39.8%
and 39.4%, respectively (Galletly et al. 2012). These
findings support the need for improved primary care
interventions for this population, and the integration
of general medical and mental health treatment
(Jerrell et al. 2012).
Across the diagnostic groups, we observed some
expected differences. Diagnostic groups differed in
terms of course of disorder, symptom profiles, social
drive (but not global independent performance) and
psychotropic medication use. The finding of signifi-
cantly lower premorbid IQ in schizophrenia compared
with bipolar disorder with psychosis is consistent with
the literature (Zammit et al. 2004). We also found that
current cognitive ability, measured by a speed of infor-
mation processing task, was significantly lower in
schizophrenia compared with both bipolar disorder
with psychosis and depressive psychosis. However,
poor physical health was pervasive, as evidenced by
high rates of the metabolic syndrome, of any of the
threshold criteria for the metabolic syndrome or its
modifiable life-style risk factors, and in the high preva-
lence of lifetime alcohol, cannabis and other substance
abuse/dependence across all diagnostic groups.
Strengths and limitations
The 2010 Australian national survey of psychosis is
one of the most comprehensive worldwide. Many of
its 1500 data items have not previously been assessed
contemporaneously and in such depth in a large,
representative, national sample. The inclusion of the
range of psychotic disorders in a sample of this size
has enabled an assessment of the specificity of findings
across the psychosis spectrum. The epidemiologi-
cal sampling design ensures that findings are
generalizable to adults in contact with public mental
health treatment services in developed countries in
similar public treatment service settings. We did not
enumerate those solely in treatment in general medical
practices or private psychiatric/psychological settings,
or homeless people not in contact with any mental
health services. We estimate that 1-month prevalence
would have risen from 3.1 to 5.3 per 1000 population,
if we had accounted for these and those in the NGO
sector (Morgan et al. 2012). In addition, we did not
enumerate those in prison or forensic mental health
services. Underestimation of prevalence may have oc-
curred if people with psychosis were missed during
screening, or if refusal/inability to participate was asso-
ciated with a higher likelihood of illness exacerbation.
However, comparison of screening data, including
symptom profiles, between interviewed participants
and those selected for interview but not participating
for any reason, indicated no systematic selection
biases. The impact of normal sampling variation,
errors in population estimates and diagnostic misclas-
sification is likely to be either negligible or to result
in underestimation of prevalence.
Conclusions
People with psychosis continue to experience poor
physical health, even though many of their risk factors
are modifiable and despite public health campaigns
aimed at these very risk factors. The World Health
Organization has identified tobacco use, high blood
pressure, overweight and obesity, physical inactivity,
high blood glucose, high cholesterol, low fruit and veg-
etable intake, and alcohol use among the 10 top risks
for mortality and disability in high-income countries
(World Health Organization, 2009). Our survey
found high rates of all eight risk factors among partici-
pants, with no significant differences between the diag-
nostic groups, highlighting urgent need for physical
health interventions across the range of psychotic dis-
orders. Moreover, the observed deficit in current cogni-
tive function and its relationship with both physical
health and global functioning suggests that cognitive
remediation must be an integral component of inter-
vention for people with psychotic illness, with import-
ant implications for workforce planning. At the same
time, further investigation is warranted into who will
have good mental and physical outcomes, and why.
One-quarter of our participants had no or only mild
impairment in global independent functioning, and
two in five did not have the metabolic syndrome.
Our data challenge services to establish comprehensive
and integrative models of recovery in order to maxi-
mize the potential for good health and quality of life
for all people with psychotic illness.
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